Abstract
The anticancer alkaloid vindesine (VDS) was conjugated to four mouse monoclonal antibodies recognizing human tumor-associated antigens. The antibodies were 96.5 (antimelanoma, IgG2a); 791T/36 (antiosteogenic sarcoma, IgG2b); 11.285.14, and 14.95.55 (anticarcinoembryonic antigen, IgG1 and IgG2a respectively). Conjugates VDS-96.5 and VDS-791T/36 were tested in vitro and shown to be specifically cytotoxic for target cells expressing the appropriate antigen. The in vivo effects of the antibodies and conjugates were tested against human tumor xenografts in athymic or immunodeprived mice using multiple treatments. Conjugate VDS-96.5 retarded the initial growth of a melanoma xenograft, whereas free antibody was without effect. Similarly, VDS-791T/36 but not free antibody retarded the growth of osteogenic sarcoma 791T. The most marked antitumor effects observed were those obtained with VDS conjugates of the anti-CEA antibodies against a colorectal tumor xenograft. Antibody 14.95.55 suppressed tumor growth both alone and as a VDS conjugate, whereas 11.285.14 produced only a slight effect alone but an almost complete and lasting suppression of tumor growth as a VDS conjugate. Free VDS had little effect at nontoxic levels. Acute studies showed that VDS-11.285.14 conjugate was considerably less toxic than free VDS in Balb/c mice.
Keywords: Melanoma, Sarcoma, Alkaloid, Osteogenic Sarcoma, Tumor Xenograft
References
- 1.Brown JP, Nishiyama K, Hellström I, Hellström KE. Structural characterization of human melanoma-associated antigen p.97 with monoclonal antibodies. J Immunol. 1981;127:539–546. [PubMed] [Google Scholar]
- 2.Conrad RA, Cullinan GJ, Gerzon K, Poore GA. Structure activity relationships of dimeric catharanthus alkaloid. 2. Experimental anti-tumor activities of N-substituted desacetyl vinblastine amide (Vindesine) sulphates. J Med Chem. 1979;22:391–400. doi: 10.1021/jm00190a008. [DOI] [PubMed] [Google Scholar]
- 3.Corvalan JRF, Axton CA, Brandon DR, Smith W, Woodhouse CS. Classification of anti-CEA monoclonal antibodies. Protides of the Biological Fluids. 1984;31:921–924. [Google Scholar]
- 4.Dillman RO, Beauregard JC, Sobol RE, Royston I, Bartholomew RM, Hagen PS, Halpern SP (1983) Complications associated with in vivo administration of anti-CEA murine monoclonal antibodies in patients with advanced colorectal carcinoma. Proc Am Ass Cancer Res, p 217
- 5.Embleton MJ, Gunn B, Byers VS, Baldwin RW. Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer. 1981;43:582–587. doi: 10.1038/bjc.1981.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Embleton MJ, Rowland GF, Simmonds RG, Jacobs E, Marsden CH, Baldwin RW. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer. 1983;47:43–49. doi: 10.1038/bjc.1983.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Farrands PA, Perkins AC, Pimm MV, Embleton MJ, Hardy JG, Baldwin RW, Hardcastle JD. Radioimmunodetection of human colorectal cancers by an anti-tumor monoclonal antibody. Lancet. 1983;1:397–400. doi: 10.1016/s0140-6736(82)90437-8. [DOI] [PubMed] [Google Scholar]
- 8.Gold P, Freeman SO. Demonstration of tumour-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–462. doi: 10.1084/jem.121.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hellström I, Hellström KE. Colony inhibition and cytotoxicity assays. In: Bloom BR, Glade PR, editors. In vitro methods in cell-mediated immunity. New York: Academic Press; 1971. pp. 409–414. [Google Scholar]
- 10.Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumour growth through interaction with effector cells. Proc Natl Acad Sci USA. 1982;79:4761–4765. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hockey M, Ford C, Newman C, Corvalan JRF, Rowland GF, Stokes H, Thompson H, Fielding JWL. The immunohistochemical localisation of carcinoembryonic antigen (CEA) with a monoclonal antibody in gastric adenocarcinomas. Br J Surg. 1983;70:300. [Google Scholar]
- 12.Johnson JR, Ford CHJ, Newman CE, Woodhouse CS, Rowland GF, Simmonds RG. A vindesine-anti-CEA conjugate cytotoxic for human cells in vitro. Br J Cancer. 1981;44:472–475. doi: 10.1038/bjc.1981.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellström I, Hellström KE. Imaging of melanoma with 131I-labelled monoclonal antibodies. J Nuclear Med. 1983;24:123–129. [PubMed] [Google Scholar]
- 14.Pimm MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson G, Baldwin RW. In vivo localisation of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer. 1982;30:75–85. doi: 10.1002/ijc.2910300114. [DOI] [PubMed] [Google Scholar]
- 15.Rowland GF, Simmonds RG, Corvalan JRF, Baldwin RW, Brown JP, Embleton MJ, Ford CHJ, Hellström KE, Hellström I, Kemshead JT, Newman CE, Woodhouse CS. Monoclonal antibodies for targeted therapy with vindesine. Protides of the Biological Fluids. 1983;30:375–379. [Google Scholar]
- 16.Rowland GF, Corvalan JRF, Axton CA, Gore VA, Marsden CH, Smith W, Simmonds RG. Suppression of growth of a human colorectal tumour in nude mice by vindesine-monoclonal antibody conjugates. Protides of the Biological Fluids. 1984;31:783–786. [Google Scholar]
- 17.Todd GC, Gibson WR, Morton DM. Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs. J Toxicol Environ Health. 1976;1:843–850. doi: 10.1080/15287397609529384. [DOI] [PubMed] [Google Scholar]